Knocking down BAZ1B or treating cells with antibodies to BAZ1B reduced cell proliferation and oncogenic pathway activation, implicating BAZ1B as a target for KRASG12 colon cancer [113]. This evidence concerns the gene BAZ1B and colonic neoplasm.